GRAIL, Inc. (GRAL) Stock
3 of the hedge funds AlphaScala tracks reported GRAL in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $7.93M. Company insiders reported 0 open-market buys and 21 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own GRAL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 116K | $7.93M | +42% |
| Renaissance Technologies Jim Simons (founder) | 9K | $628.1K | -83% |
| Marshall Wace | 6K | $423.4K | -90% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are GRAIL, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Ofman Joshua J. | Chief Executive Officer | SELL | 400 | $53K |
| Oct 15, 26 | Ofman Joshua J. | Chief Executive Officer | SELL | 1.0K | $134K |
| Oct 15, 26 | Ofman Joshua J. | Chief Executive Officer | SELL | 3.4K | $461K |
| Oct 15, 26 | Ofman Joshua J. | Chief Executive Officer | SELL | 7.1K | $965K |
| Oct 15, 26 | Ofman Joshua J. | Chief Executive Officer | SELL | 6.0K | $830K |
| Oct 15, 26 | Ofman Joshua J. | Chief Executive Officer | SELL | 2.1K | $293K |
| Oct 5, 26 | Freidin Aaron | Chief Financial Officer | SELL | 23.6K | $3.5M |
| Oct 5, 26 | Partridge Andrew John | Chief Growth Officer | SELL | 7.9K | $1.2M |
| Sep 21, 26 | Ofman Joshua J. | Chief Executive Officer | SELL | 2.1K | $196K |
| Sep 21, 26 | Ofman Joshua J. | Chief Executive Officer | SELL | 1.5K | $136K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →GRAL price chart
Powered by TradingViewWhat does GRAIL, Inc. do?
Grail, Inc. is a biotechnology company headquartered in Menlo Park, California, founded in 2015. The company focuses on alleviating the global burden of cancer through innovative multi-cancer early detection technologies. Its flagship product, the Galleri test, is a blood-based liquid biopsy that screens for multiple deadly cancer types at earlier, potentially more treatable stages, including those without existing recommended screening methods. Grail leverages next-generation sequencing, population-scale clinical studies, state-of-the-art machine learning, software, and automation to detect cancer signals from circulating cell-free DNA in the blood. The company conducts large-scale trials, such as the NHS-Galleri trial and PATHFINDER 2 study, to validate and refine its offerings. Grail also explores diagnostic aids for cancer suspicion and minimal residual disease monitoring. Operating in the healthcare and life sciences sectors, it partners with academic institutions, healthcare providers, and organizations to advance early cancer detection and improve patient outcomes worldwide.